订阅小程序
旧版功能

The First-in-class Bispecific Antibody IBI318 (LY3434172) Targeting PD-1 and PD-L1 in Patients with Advanced Tumors: a Phase Ia/Ib Study

Journal of Hematology & Oncology(2024)

引用 0|浏览3
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要